WuXi Biologics Celebrates ESG Achievements with Double Honors at 2026 HERA

WuXi Biologics Recognized for Excellence in ESG Reporting

On November 3, 2026, WuXi Biologics, a prominent global Contract Research, Development, and Manufacturing Organization (CRDMO), proudly announced its remarkable achievement of receiving two Grand Awards at the ninth Hong Kong ESG Reporting Awards (HERA). These awards recognize the company's outstanding performance in the areas of sustainability and governance, namely the Best ESG Report for Large-Cap companies and the Excellence in Environmental Positive Impact category.

HERA is renowned for celebrating organizations that excel in sustainability reporting and environmental, social, and governance (ESG) practices. With various award categories dedicated to different ESG aspects, including governance, carbon neutrality, and social impact, the awards are evaluated by an independent panel of experts from academia, finance, and sustainability advisory roles. This process not only highlights excellence in reporting but also promotes accountability and stakeholder confidence.

Out of 120 submissions, WuXi Biologics stood out as the only pharmaceutical company to secure a Grand Award this year. This recognition underscores the company's relentless commitment to transparent and high-quality ESG disclosure, along with its measurable environmental advancements across its global operations. Dr. Chris Chen, the CEO of WuXi Biologics and Chair of its ESG Committee, expressed his delight at receiving the awards, emphasizing that continuous transparency in ESG disclosure coupled with robust environmental performance is crucial for long-term business resilience and success.

Dr. Chen stated, "We are thrilled to receive two HERA awards, reflecting our strong belief that effective ESG practices are critical to our business framework. WuXi Biologics is dedicated to improving our ESG governance and advancing our Green CRDMO strategy, collaborating with partners worldwide to foster sustainable development throughout the value chain."

Among WuXi Biologics' ongoing initiatives are its Green CRDMO solutions, which embed sustainability principles across all levels of biologics research, development, and manufacturing processes. In 2025, the company set ambitious greenhouse gas emissions reduction targets that were validated by the Science Based Targets initiative (SBTi), covering Scope 1, 2, and 3 emissions and aligning with the global 1.5°C temperature goal.

In addition to the recent HERA awards, WuXi Biologics was also named to the 2026 Forbes China ESG 50 list, a distinction that celebrates its achievements in sustainable development, Green CRDMO solutions, and digital innovation in the ESG landscape.

About WuXi Biologics

Established as a leader in the global CRDMO space, WuXi Biologics (2269.HK) provides end-to-end solutions that empower partners from concept through to commercialization in discovering, developing, and manufacturing biologics. With over 14,000 professionals spread across locations such as China, the United States, Ireland, Germany, and Singapore, the company combines expert insights with cutting-edge technology to deliver scalable, cost-effective biosolutions aligned with clients' unique needs.

WuXi Biologics prioritizes embedding digital capability across the biopharmaceutical value chain, transforming data and analytics into a superior client experience, accelerated development, intelligent operations, and streamlined production. As of June 30, 2026, the organization supports 1,064 integrated client projects, with 78 projects in Phase III and 28 in commercial manufacturing, demonstrating its extensive involvement in advanced biologics development.

Sustainability serves as the foundation of WuXi Biologics' growth strategy, as it continuously aims to drive technological innovations in Green CRDMO solutions for its partners. The company actively fosters collaborations to create shared value, encouraging positive social and environmental impacts while promoting responsible practices across the entire value chain.

To learn more about WuXi Biologics, visit www.wuxibiologics.com.